Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-Satoreotide in Recurrent or Progressive Meningiomas
NCT04997317Phase 2Recruiting
- Sponsor
- University Hospital Basel
- Start
- Apr 2021
- Primary completion
- Dec 2026
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of satoreotide tetraxetan in meningioma, sponsored by University Hospital Basel. Started Apr 2021; status: recruiting.
02
Drugs
satoreotide tetraxetan
03
Conditions
meningioma
Beyond the preview
Go deeper on NCT04997317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04997317.